TearLab plans $15 million public sale of class A units, class B units

Stock, convertible preferreds sold with warrants by H.C. Wainwright

By Devika Patel

Knoxville, Tenn., March 22 – TearLab Corp. will price a $15 million public sale of class A units and class B units, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $15 million of underlying stock.

The class A units will consist of common stock and warrants, and the class B units will consist of series A convertible preferred stock and warrants. Each preferred is convertible into common stock.

H.C. Wainwright & Co., LLC is the agent.

Proceeds will be used for general corporate purposes.

The San Diego company develops and markets lab-on-a-chip technologies that enable eye care practitioners to test for disease markers in tears.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.